Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives.

Hasselbalch HC, Larsen TS, Riley CH, Jensen MK, Kiladjian JJ.

Curr Drug Targets. 2011 Mar 1;12(3):392-419. Review.

PMID:
21143149
2.

A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.

Hasselbalch HC.

Expert Rev Hematol. 2011 Dec;4(6):637-55. doi: 10.1586/EHM.11.63. Review.

PMID:
22077528
3.

[Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].

Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.

Vnitr Lek. 2011 Feb;57(2):189-213. Review. Czech.

PMID:
21416861
4.

Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.

Stein BL, Tiu RV.

J Interferon Cytokine Res. 2013 Apr;33(4):145-53. doi: 10.1089/jir.2012.0120. Review.

PMID:
23570380
5.
6.

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.

Eur J Haematol. 2007 Dec;79(6):508-15. Epub 2007 Oct 23.

PMID:
17961178
7.

Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.

Kiladjian JJ, Chomienne C, Fenaux P.

Leukemia. 2008 Nov;22(11):1990-8. doi: 10.1038/leu.2008.280. Epub 2008 Oct 9. Review.

PMID:
18843285
8.

Myeloproliferative neoplasia: a review of clinical criteria and treatment.

Koopmans SM, van Marion AM, Schouten HC.

Neth J Med. 2012 May;70(4):159-67. Review.

9.

Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.

Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJ, Brière J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbalch H, Cervantes F, Thiele J, et al.

Neth J Med. 1999 Feb;54(2):46-62. Review.

PMID:
10079679
10.

Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.

Radin AI, Kim HT, Grant BW, Bennett JM, Kirkwood JM, Stewart JA, Hahn RG, Dutcher JP, Wiernik PH, Oken MM; Eastern Cooperative Oncology Group..

Cancer. 2003 Jul 1;98(1):100-9.

11.

PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.

Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Faderl S, Richie MA, Beran M, Giles F, Verstovsek S.

Cancer. 2007 Nov 1;110(9):2012-8.

12.

Interferon in the treatment of myeloproliferative diseases.

Silver RT.

Semin Hematol. 1990 Jul;27(3 Suppl 4):6-14. Review.

PMID:
2115694
13.

Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.

Stauffer Larsen T, Iversen KF, Hansen E, Mathiasen AB, Marcher C, Frederiksen M, Larsen H, Helleberg I, Riley CH, Bjerrum OW, Rønnov-Jessen D, Møller MB, de Stricker K, Vestergaard H, Hasselbalch HC.

Leuk Res. 2013 Sep;37(9):1041-5. doi: 10.1016/j.leukres.2013.06.012. Epub 2013 Jul 1.

PMID:
23827351
14.
15.

Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.

Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.

Semin Thromb Hemost. 2006 Apr;32(3):174-207. Review.

PMID:
16673274
16.
17.

Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.

Silver RT, Kiladjian JJ, Hasselbalch HC.

Expert Rev Hematol. 2013 Feb;6(1):49-58. doi: 10.1586/ehm.12.69.

PMID:
23373780
18.

Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera.

Utke Rank C, Weis Bjerrum O, Larsen TS, Kjær L, de Stricker K, Riley CH, Hasselbalch HC.

Leuk Lymphoma. 2015 Jun 18:1-7. [Epub ahead of print]

PMID:
25956046
19.

Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.

Pikman Y, Levine RL.

Curr Opin Oncol. 2007 Nov;19(6):628-34. Review.

PMID:
17906464
20.

Future therapies for the myeloproliferative neoplasms.

Scherber R, Mesa RA.

Curr Hematol Malig Rep. 2011 Mar;6(1):22-7. doi: 10.1007/s11899-010-0068-4. Review.

PMID:
21080242

Supplemental Content

Support Center